Haineng Technology: Plans to establish a wholly-owned subsidiary with an investment of 500 million yuan to integrate its bioenergy business.

Haixin Nengke announced that the company passed a resolution on August 7, 2026, to establish a wholly-owned subsidiary, Haixin Biology, with a registered capital of 500 million yuan. The company plans to transfer its holdings of 84.6154% in Shandong Sanju and 100% in Haixin International to this subsidiary at net asset value. In the first quarter of 2026, Shandong Sanju reported revenue of 487 million yuan and a net profit of 5.1868 million yuan, while Haixin International reported revenue of 496 million yuan and a net profit of 25.8715 million yuan. This integration does not constitute a major asset reorganization and will not have a significant adverse impact on the financial and operational results.